CORRECTION article

Front. Pharmacol., 18 December 2023

Sec. Ethnopharmacology

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1297863

Corrigendum: Inhibitory effects of Rhaponticin on osteoclast formation and resorption by targeting RANKL-induced NFATc1 and ROS activity

  • 1. The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicin, Zhuhai, China

  • 2. School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia

  • 3. Department of Orthopedics, First People’s Hospital of Nanning, Fifth Affiliated Hospital of Guangxi Medical University, Nanning, China

  • 4. The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

  • 5. Formula-Pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China

Article metrics

View details

2

Citations

1,3k

Views

518

Downloads

In the published article, there was an error in Figure 3A about the 50 μM TRAcP picture as published. Two pictures were taken from the same cell culture well with 25 μM treatment, and partially overlapped images were obtained during photo taking, because both were from the same well. However, one image was placed as a 50 μM group, which occurred during the process of PowerPoint figure preparation due to an oversight. The corrected Figure 3 appears below.

FIGURE 3

FIGURE 3

RH attenuated osteoclast hydroxyapatite resorption and osteoclast-specific genes expression. (A) Representative images of the resorption on hydroxyapatite-coated plates and TRAcP staining after treatment of RH for 48 hr. (B) Quantification of TRAcP-positive osteoclasts numbers per well (n = 3). (C) Quantification of resorption area on hydroxyapatite surface per osteoclast (n = 3). (D–G) PCR results of osteoclast-specific genes Nfatc1, c-Fos, Ctsk, and Atp6v0d2. Gene expression levels were standardized to Hprt expression. *p < 0.05, **p < 0.01 relative to RANKL-induced control group. Scale bar = 200 μm.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

osteoclast, NFATc1, ROS, rhaponticin, bone

Citation

He J, Chen K, Deng T, Xie J, Zhong K, Yuan J, Wang Z, Xiao Z, Gu R, Chen D, Li X, Lin D and Xu J (2023) Corrigendum: Inhibitory effects of Rhaponticin on osteoclast formation and resorption by targeting RANKL-induced NFATc1 and ROS activity. Front. Pharmacol. 14:1297863. doi: 10.3389/fphar.2023.1297863

Received

20 September 2023

Accepted

27 November 2023

Published

18 December 2023

Volume

14 - 2023

Edited and reviewed by

Wenzhi Yang, Tianjin University of Traditional Chinese Medicine, China

Updates

Copyright

*Correspondence: Xiaojuan Li, ; Dingkun Lin, ; Jiake Xu,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics